Also visit: Boxxet
 

# 10 Blogger

sev.prnewswire.com

sev.prnewswire.com (sev.prnewswire.com) has great Diabetes news, photos, videos and more

If you publish sev.prnewswire.com or are a publisher of a great blog, join THE BOXXET NETWORK.

Monday, Jun 8

Tolerx Presents Data at 69th Scientific Sessions of the American ... - PR Newswire

PR Newswire (press release), NY In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer ...

Diamyd(R) Phase III Study Approved for Younger Patients in the US - PR Newswire

PR Newswire (press release), NY STOCKHOLM, June 8 /PRNewswire/ -- Diamyd Medical reported today that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company's Phase III study with ...

Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With ... - PR Newswire

PR Newswire (press release), NY This post-hoc analysis of two 12-week, randomized phase 3 studies of patients with mixed dyslipidemia examined a subgroup of 480 patients with type 2 diabetes. These patients were required to have an LDL greater than or equal to 130 mg/dL, ...

Saturday, Jun 6

Boehringer Ingelheim Unveils Diabetes Pipeline - PR Newswire

Results from the Phase II study presented at ADA show that 1, 5 and 10 mg doses of linagliptin achieved clinically relevant and statistically significant reductions in HbA1c, a measure of blood sugar, when given as add-on therapy to type 2 diabetes ...

Friday, May 29

Amylin Pharmaceuticals to Present Compelling Efficacy and Safety ... - PR Newswire

SYMLIN is a synthetic analog of human amylin, a naturally occurring hormone that is made in the beta cells of the pancreas, the same cells that make insulin. In patients with type 2 diabetes who use insulin, and in patients with type 1 diabetes, ...

Tuesday, May 19

New Report Shows Record Number of Medicines Currently in ... - PR Newswire

A medicine that that addresses the underlying cause of type 2 diabetes by modulating genes responsible for insulin sensitization. A medicine that stimulates the release of insulin only when glucose levels become too high and by suppressing appetite in ...

Monday, May 18

Joslin Diabetes Center Names Boston Celtics Star Ray Allen to ... - PR Newswire

BOSTON, May 18 /PRNewswire-USNewswire/ -- Joslin Diabetes Center today announced that it has appointed Boston Celtics star guard Ray Allen to its Board of Trustees. Allen is the father of a child with type 1 diabetes. In June 2008, while the Celtics ...

Type 2 Diabetes: An Epidemic Among America's Youth - PR Newswire

Researchers are tracking the youth's body mass indices (BMIs), fasting glucose levels and fasting insulin levels to show the health benefits of lifestyle adjustments. TODAY, the second trial, is exploring the best treatment options for children with ...

Monday, May 11

Amylin Sends Letter To Shareholders - PR Newswire

PR Newswire (press release), NY Last year there were over 23 million people with diabetes in the United States alone. Exenatide once weekly will be the first once-a-week treatment for type 2 diabetes and has the potential to transform the treatment of the disease. ...

Friday, May 8

New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil ... - PR Newswire

PR Newswire (press release), NY This study also showed that an amlodipine and olmesartan medoxomil-based titration regimen can be an effective tool for treating hypertension in more challenging patient populations, such as patients with type 2 diabetes and Blacks. ...

Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood ... - PR Newswire

Thumbnail Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir(R) should not be diluted or mixed with any other insulin preparations. Insulin may cause sodium retention ...

 
 

Do you publish a blog? If so, consider joining the Boxxet Network and see your great content showcased and rewarded! Learn more...

©2009 Boxxet, Inc. | Contact | Privacy Policy | Terms of Service
Page updated Fri, Feb 5.